Please wait while the formulary information is being retrieved.
VONJO (pacritinib citrate)
- Myelofibrosis
100 mg capsule
- 2 capsules (200 mg) by oral route 2 times per day
Default screening record
- 1 capsule (100 mg) by oral route 2 times per day
- 1 capsule (100 mg) by oral route once daily
- 2 capsules (200 mg) by oral route 2 times per day
- natalizumab
- Tysabri
Contraindicated
- None
Severe
Moderate
- None
- Child-pugh class B hepatic impairment
- Child-pugh class C hepatic impairment
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Disease of liver
- Lactation
Contraindicated
- Congenital long QT syndrome
- Diarrhea
- Hemorrhage
- Hypokalemia
- Increased risk of atherosclerotic cardiovascular disease
- Kidney disease with likely reduction in GFR
- Malignancy
- Malignant lymphoma
- Pregnancy
- Prolonged QT interval
- Severe infection
- Thrombocytopenic disorder
- Thrombotic disorder
Severe
Moderate
- None
VONJO (pacritinib citrate)
- Myelofibrosis
- Anemia
- Thrombocytopenic disorder
- Diarrhea
- Nausea
- Peripheral edema
More Frequent
Severe
Less Severe
- Heart failure
- Hemorrhage
- Neutropenic disorder
- Pneumonia
- Conjunctival hemorrhage
- Cough
- Dizziness
- Dyspnea
- Epistaxis
- Fever
- Pruritus of skin
- Squamous cell carcinoma of skin
- Upper respiratory infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Prolonged QT interval
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Pacritinib
Safety and effectiveness not established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients.
Pacritinib
- Severity Level:
D
- Additional Notes: Insuff human data; consider maternal benefit vs.poss fetal risk
Contraindicated
Pacritinib
Pot for serious adv eff; manuf rec not breastfeed dur tx and for 2 wks after
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Pot for serious adv eff; manuf rec not breastfeed dur tx and for 2 wks after |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Myelofibrosis | |
| D47.4 | Osteomyelofibrosis |
| D75.81 | Myelofibrosis |
| 0-9 | A-Z |
|---|---|
| D47.4 | Osteomyelofibrosis |
| D75.81 | Myelofibrosis |
Formulary Reference Tool